Corazon Gold Corp. (the “Company”) and NanoSphere Health Sciences, LLC (“NanoSphere”) are pleased to announce the closing of the Company’s private placement (the “Offering”) for gross proceeds of $5,905,685, and the completion of the Company’s acquisition (the “Acquisition”) of NanoSphere. Based upon the CSE’s conditional listing approval, the Company will make its final submission for CSE listing in short order, and concurrently with its listing on the CSE will change its name to “NanoSphere Health Sciences Inc.” and effect a de-listing from the TSX Venture Exchange.
“The completion of this financing and merger represents a significant step in unlocking the opportunity to become a true market leader,” said David Sutton, President and COO of the Company. For over two decades, NanoSphere’s scientists have researched and developed the revolutionary NanoSphere Delivery System™ to meet the needs of consumers, healthcare providers, and suppliers. The NanoSphere Delivery System™ employs nanotechnology in the delivery of biological compounds for improved bioavailability, efficacy, and onset of effect. Under the brand “Evolve”, Nanosphere has already launched its acclaimed NanoSerum™ product for the recreational and medical cannabis markets in Colorado. NanoSerum™ is the first clinically-tested transdermal cannabis product to relieve pain in minutes, and we intend to build on that success by opening new markets for Evolve and developing new applications for NanoSerum™.